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SummAry
The purpose of this report is to review the relationship between genetic polymorphisms involved in carcinogen metabolism, alcohol me-
tabolism and cell-cycle control with the risk of head and neck cancer. The review was performed on available studies on genetic polymor-
phisms and head and neck cancer (hnC) published in Pubmed up to September 2011. 246 primary articles and 7 meta-analyses were pub-
lished. Among these, a statistically significant association was reported for glutathione S-transferases (GSTM1), glutathione S-transferases 
(GSTT1) and human microsomal epoxide hydrolase (EPHX1) genes. An increased risk for hnC was also associated reported for P53 codon 
72 Pro/Pro, ALDH2 and three variants of the ADH gene: ADH1B (rs1229984), ADH7 (rs1573496) and ADH1C (rs698).
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riASSunTo
Lo scopo di questo lavoro è stato valutare la relazione esistente tra i polimorfismi dei geni coinvolti nella carcinogenesi testa- collo, nel 
metabolismo dell’alcool e nel controllo del ciclo cellulare e il rischio di sviluppare un tumore della testa e del collo (HNC). La revisione è 
stata effettuata su studi relativi ai polimorfismi genetici e al cancro testa collo (HNC) pubblicati su PubMed fino al settembre 2011. I risul-
tati hanno mostrato l’esistenza di 246 articoli primari e 7 meta-analisi. Tra queste, una associazione statisticamente significativa è stata 
segnalata per la glutatione S-transferasi (GSTM1), glutatione S-transferasi (GSTT1) e Human microsomal epoxide hydrolase (EPHX1) 
geni. Un aumentato rischio di sviluppo del tumore testa collo è stato inoltre associato alla presenza della variante di P53 codone 72 Pro/
Pro, di ALDH2, e delle tre varianti del gene ADH: ADH1B (rs1229984), ADH7 (rs1573496) e ADH1C (rs698). 
PArole ChiAve: Tumore testa-collo • Suscettibilità genetica • Polimorfismi genetici
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Introduction
head  and  neck  cancers  (hnC),  including  oral  cavity, 
oropharynx, hypopharynx and larynx are among the most 
common types of cancer and represent a major health prob-
lem 1.  There  are  approximately  540,000  new  cases  and 
271,000 deaths annually worldwide for a mortality of ap-
proximately 50%. hnC represent approximately 3% of all 
cancers in the united States 2, but are much more prevalent 
in some parts of South America (Brazil, uruguay and Ar-
gentina) 1. development of hnC is a multifactorial proc-
ess associated with a variety of risk factors. Tobacco and 
alcohol consumption are established risk factors for hnC 
(synergistic in persons who both smoke tobacco and drink 
alcohol), even though other factors may affect risk 3 4. in 
developing countries, other factors, like betel and tobacco 
chewing, human papillomavirus infection or drinking hot 
beverages, also play an important role 1. in recent years, ev-
idence has accumulated to support the hypothesis that diet 
may also play an important aetiological role in development 
of disease, and 10-15% of squamous cell carcinoma of the 
head and neck (SCChn) cases in europe are associated 
with a low intake of fruit and vegetables 5-8. A family history 
of cancer is another important risk factor for hnC 9, which 
implies that genetics contributes to hnC susceptibility 10.
Materials and methods
herein, we review the published studies concerning ge-
netic susceptibility to hnC. A variety of genes are associ-g. Cadoni et al.
2
ated with hnC carcinogenesis, including those involved 
in  carcinogen  metabolism,  alcohol  metabolism,  folate 
metabolism,  dnA  repair,  cell-cycle  control  and  onco-
genes 2. we have focused our attention on genes involved 
in carcinogen metabolism, alcohol metabolism and cell-
cycle control.
A  Pubmed  search  was  performed  until  to  the  end  of 
September 2011. The following terms were used: head 
and neck and cancer (with both synonymous and plural 
forms), as well as the truncated words genetic*, allel*, or 
polymorphi*.
Results
The literature search identified the below list of genes:
•  Cytochrome P450 2E1 (CYP2E1);
•  Cytochrome P450 1A1 (CYP1A1);
•  Glutathione S-transferase (GSTM1);
•  Glutathione S-transferase (GSTT1);
•  Glutathione S-transferase (GSTP1);
•  N-acetyltransferase 2 (NAT2);
•  Human microsomal epoxide hydrolase (EPHX1);
•  Aldehyde dehydrogenase 2 (ALDH2);
•  Alcohol dehydrogenase isoenzymes (ADH);
•  X-ray repair cross complementary 1 (XRCC1);
•  Xeroderma  pigmentosum  complementary  group  D 
(XPD);
•  Cyclin D1 (CCND1);
•  P53 tumour suppressor;
•  P73.
Tables i and ii report, respectively, a summary of primary 
studies of genetic polymorphisms in genes involved in 
carcinogen metabolism, alcohol metabolism and cell-cy-
cle control and the risk of hnC, and a summary of meta-
analyses of genetic polymorphisms of the aforementioned 
gene classes and hnC risk.
Below we discuss the significance of each gene in the ae-
tiology of hnC:
•  Cytochrome  P450  2E1  (CYP2E1),  a  member  of  the 
cytochrome P-450 superfamily, is a naturally ethanol-
inducible phase i enzyme. it is mainly involved in the 
metabolic  activation  of  low  molecular  weight  com-
pounds such as nitrosamines and alcohol metabolism 11. 
The variant c2 allele, which contains a novel rsai/Psti 
site in the 5’-flanking region of the CYP2E1 gene, ap-
pears to be associated with decreased enzyme activity. 
Ten 12-21 of the 15 studies 12-25 published before July 2007 
suggested that the c1/c2 genotype of CYP2E1 may in-
crease risk for hnC compared with the c1/c1 geno-
type. results of 6 14 16 18 21 22 24 of 7 studies 13 14 16 18  21  22 24 
suggested that the c2/c2 genotype may increase risk for 
hnC 2.
•  Cytochrome P450 1A1 (CYP1A1) is an important phase 
i enzyme that plays an essential role in the metabolic 
activation  of  major  classes  of  pro-carcinogens  such 
as benzopyrene, a prototypic polycyclic aromatic hy-
drocarbon 26. An ile-val substitution in codon 462 of 
CYP1A1, which is in the haem-binding region, results 
in a 2-fold increase in microsomal enzyme activity and, 
in Caucasians, is in complete linkage disequilibrium 
with the CYP1A1 mspi polymorphism, which is also 
associated with increased catalytic activity. we identi-
fied some studies related to the association of CYP1A1 
with hnC risk published before July 2007, regarding 
the relation of the CYP1A1 ile-val substitution at co-
don 462 to hnC. in 4 studies 27-30, the risk for hnC in 
subjects with the ile/val and/or val/val genotypes was 
significantly higher than that for subjects with the ile/
ile genotype, suggesting that the val allele may be as-
sociated with increased risk for hnC. A meta-analysis 
of studies that examined the association of the CYP1A1 
ile-val substitution with risk for hnC revealed that the 
ile/val and val/val genotypes tend to increase hnC 
risk with an odds ratio (or) [95% confidence interval 
(Ci)] compared with ile/ile of 1.32 (0.95-1.82). Suc-
cessive studies suggest that significant differences in 
the  distribution  of  certain  haplotypes  of  CYPs  have 
been reported, and the prevalence of certain genotype 
combinations of CYPs and GSTS has indicated the im-
portance of gene-gene interactions in hnSCC risk 31  32. 
The pooled data indicated that CYP1A1 mspi poly-
morphism might be a risk factor for laryngeal cancer, 
particularly in Caucasians. For Asians, it might slightly 
increase the susceptibility to laryngeal cancer. howev-
er, the data failed to demonstrate a marked association 
between the CYP1A1 exon 7 polymorphism and laryn-
geal cancer risk 26. The CYP1A1 exon 7 polymorphism 
Table I. Summary of primary studies of genetic polymorphisms and HNC 
risk.
Gene and polymorphism No. of included studies
Cytochrome P450 2E1 (CYP2E1) 15
Cytochrome P450 1A1 (CYP1A1) codon 462 9
Glutathione S-transferase (GSTM1) 20
Glutathione S-transferase (GSTT1) 9
Glutathione S-transferase (GSTP1) 22
N-acetyltransferase 2 (NAT2) 11
Human microsomal epoxide hydrolase 
(EPHX1)
91
Aldehyde dehydrogenase 2 (ALDH2) 8
Alcohol dehydrogenase isoenzymes (ADH) 12
X-ray repair cross complementary 1 
(XRCC1)
2
Xeroderma pigmentosum complementary 
group D (XPD)
6
Cyclin D1 (CCND1) 12
P53 tumour suppressor gene 26
P73 3genetic susceptibility to head-neck cancer
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was associated with oral and pharyngeal cancer only 
for ever smokers, when studied independently in the 
pooled analysis, although the CYP1A1 mspi variant ho-
mozygote allele (m2/m2) was significantly associated 
with this cancer in both the meta-analysis and pooled 
analysis. when  analyzing  the  complete  genotype  of 
GSTM1 deletion and CYP1A1 mspi polymorphism, the 
risk of oral and pharyngeal cancers seems to be higher 
for never smokers than for ever smokers. it should be 
highlighted that the results of the pooled analysis var-
ied according to the type of controls considered, indi-
cating that a selection bias might be present in some 
studies, and therefore the results should be considered 
with caution. There is no indication for population test-
ing of these genes as risk factors for oral and pharyn-
geal cancer 33. overall, Zhou et al. 2009 reported that 
variant genotypes of CYP1A1 might not be risk factors 
for oral cancer.
•  The glutathione S-transferases are a family of phase 
ii  xenobiotic  metabolizing  enzymes  catalyzing  the 
conjugation reactions of reactive intermediates of elec-
trophilic compounds with cytosolic glutathione. Based 
on sequence similarities, human cytosolic glutathione 
S-transferases are mainly coded for at 5 loci: GSTA (a), 
GSTT1 (h), GSTM1 (l), GSTP1 (p), and GSTM3 (c). 
Polymorphisms  in  these  genes,  possibly  by  altering 
their expression and functional activities, may affect 
carcinogen activation/detoxification and dnA repair. 
Three alleles have been identified at the glutathione S-
transferase m1 (GSTM1) locus: GSTM1*0, GSTM1*A, 
and GSTM1*B. Two major alleles have been identi-
fied at the glutathione S-transferase T1 (GSTT1) locus: 
GSTT1*1 and GSTT1*0. Previous studies showed that 
a homozygous deletion (0/0), or null genotype, at ei-
ther the GSTM1 locus or the GSTT1 locus resulted in 
enzyme function loss 32-34, and thus it was hypothesized 
to be related to the susceptibility to hnC.
•  For HNCs since July 2007, 36 ORs from 58 studies 
of the null GSTM1 genotype vs the positive genotype 
were > 1, suggesting that the null GSTM1 genotype 
may be associated with increased risk for hnC. Six-
teen 17 35-49 of the studies showed a significantly higher 
risk for hnC in subjects with the null GSTM1 geno-
type than in subjects with the positive genotype. Two 
meta-analyses 50 51 of studies that examined the asso-
ciation of GSTM1 with risk for hnC revealed that the 
null genotype significantly increases the risk with ors 
(95%Ci) of 1.23 (1.06-1.42) and 1.50 (1.21-1.87) com-
pared with the positive genotype 2. Successive studies 
suggest that GSTM1 has been reported to detoxify the 
bioreactive diol-exoxides of PAhs, which is important 
in environmental and occupational carcinogenesis. The 
data supported that GSTM1 deficiency was associated 
with laryngeal cancer risk.
•  We identified 23 ORs from 42 studies published before 
July 2007 of the null GSTT1 genotype vs the positive 
genotype that were > 1, and 7 studies 39 44 48 52-55 show-
ing a significantly higher risk for hnC in subjects with 
the null genotype than with the positive genotype, sug-
gesting that the null GSTT1 genotype may be associ-
ated with increased risk for hnC. A meta-analysis 50 of 
studies that examined the association of GSTT1 with 
risk of hnC revealed that the null genotype tends to 
increase hnC risk with ors (95%Ci) of 1.17 (0.98-
1.40) compared with positive genotype 2.
•  For GSTP1, four 56-59 of the 21 studies 14 47 56-74 showed 
a significantly higher risk for hnC in individuals with 
the ile/val and/or val/val genotypes than in those with 
the ile/ile genotype. no studies showed a significantly 
lower risk with the ile/val and/or val/val genotypes 
Table II. Summary of previous meta-analyses of genetic polymorphisms and HNC risk.
Gene and polymorphism Authors and year No. of studies included Associations studied OR (95%CI)
Cytochrome P450 1A1 (CYP1A1) 
codon 462 Hashibe et al., 2003 50 12 Ile/Val+Val/Val vs. Ile/Ile 1.32 (0.95-1.82)
Glutathione S-transferase (GSTM1)
Hashibe et al., 2003 50 30 Null vs. Positive 1.23 (1.06-1.42)
Tripathy & Roy, 2006 51 30 Null vs. Positive 1.50 (1.21-1.87)
Glutathione S-transferase (GSTT1) Hashibe et al., 2003 50 21 Null vs. Positive 1.17 (0.98-1.40)
Glutathione S-transferase (GSTP1) Hashibe et al., 2003 50 9 Ile/Val+Val/Val vs. Ile/Ile 1.10 (0.92-1.31)
N-acetyltransferase 2 (NAT2) Ying et al., 2011 80 7
Slow acetylators vs. cancer 0.99 (0.71-.38)
Rapid acetylators vs. cancer 1.01 (0.72-.40)
Human microsomal epoxide 
hydrolase (EPHX1) Li et al., 2011 83 82
Y113H allele vs. cancer 0.86 (0.77-0.97)
H139R allele vs. cancer 1.05 (0.93-1.17)
(RR) of H139R allele vs. 
cancer 1.34 (0.98-1.82)
XRCC1 codon 194
Hu et al., 2005 149 3 Arg/Trp+Trp/Trp vs. Arg/Arg 0.85 (0.59-1.23)
XRCC1 codon 399 4 Gln/Gln vs. Arg/Arg 1.13 (0.81-1.58)g. Cadoni et al.
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than the ile/ile genotype. The 105 val allele might be 
associated with an increased risk for hnC. one meta-
analysis revealed that the ile/val and val/val genotypes 
tend to increase hnC risk with ors (95%Ci) of 1.10 
(0.92-1.31) compared with the positive genotype 3 50. 
There have been no studies after July 2007 investigat-
ing the correlation between hnC and GSTP1.
•  Human arylamine N-acetyltransferases play a key role 
in the metabolism of drugs and environmental chemi-
cals and in the metabolic activation and detoxification 
of procarcinogens. Phenotyping analyses have revealed 
an association between NAT enzyme activities and the 
risk of developing several forms of cancer 32 75. The 
NAT2 isoenzyme functions to both activate and deac-
tivate arylamine and hydrazine drugs and carcinogens. 
Polymorphisms in this gene are responsible for the n-
acetylation polymorphism in which human populations 
segregate into rapid, intermediate and slow acetylator 
phenotypes. Polymorphisms in NAT2 are also associ-
ated with higher incidences of cancer and drug toxicity. 
A second arylamine N-acetyltransferase gene (NAT1) 
is located near NAT2 (refSeq, Jul 2008). For hnC, all 
7 ors 14 23 64 76 for the slow NAT2 genotype vs the rap-
id genotype were > 1, suggesting that the slow nAT2 
genotype may be associated with an increased risk for 
hnC 2. ying XJ 80, in his meta-analysis published in 
2011, claimed that there was overall lack of association 
between  NAT2  polymorphism  and  laryngeal  cancer 
risk; however, NAT2 slow acetylation may contribute 
to a risk factor for laryngeal cancer in Asians, but not 
in Caucasians. in 2008, Buch 81 published results that 
demonstrated how fast NAT2 acetylation was a risk fac-
tor for oral cancer. demokan in 2010 82 published that 
NAT1 and NAT2 gene combinations may influence the 
risk of developing head and neck cancer.
•  Human microsomal epoxide hydrolase (EPHX1) plays 
an important role during xenobiotic detoxification of ex-
ogenous chemicals such as polycyclic aromatic hydro-
carbons (PAhs), which are produced during the use of 
coal tar, coke, bitumen or during cigarette smoking 32  83. 
Two  amino  acid-altering  polymorphisms, Tyr113his 
and his139Arg, have been identified in EPHX1 and 
both are associated with alterations in meh activity. 
The EPHX1 his113 variant shows a 40% decrease in 
eh activity, whereas the EPHX1 Arg139 variant shows 
25%  increased  enzyme  activity 2.  A  comprehensive 
systematic review of available studies published up to 
2011, consisting of 91 studies, 84 (31,144 cases and 
42,439 controls) for Tyr113his and 77 (28,496 cases 
and 38,506 controls) for his139Arg 83. results of anal-
ysis of these two polymorphisms in different cancer 
types revealed that the low activity allele (h) of y113h 
was highly associated with decreased risk of lung can-
cer (or = 0.88, 95%Ci = 0.80-0.96; p = 0.005) and 
hnC (or = 0.86, 95%Ci = 0.77-0.97; p = 0.014); the 
high activity allele (r) of h139r was significantly as-
sociated with increased risk of lung cancer (or = 1.18, 
95%Ci  =  1.04-1.33;  p  =  0.010),  but  not  of  hnC 
(or = 1.05, 95%Ci = 0.93-1.17, p = 0.447). however, 
the homozygous variant (rr) of h139r showed in-
creased risk of hnC (or = 1.34, 95%Ci = 0.98-1.82, 
p = 0.065).
•   Aldehyde dehydrogenase 2 (ALDH2) is a key gene in 
alcohol  metabolism,  and  determines  blood  acetalde-
hyde concentrations after drinking 10. A single point al-
teration in Aldh2 results in the ALDH2*2 allele. The 
protein encoded by ALDH2*2 has a glu to lys substitu-
tion at residue 487, resulting in an inactive subunit and 
the inability to metabolize acetaldehyde. The ALDH2*2 
allele is rare in western populations, but prevalent in 
east  Asian  populations.  ALDH2*2/*2  homozygotes 
have serum acetaldehyde levels that are 13 times higher 
and heterozygotes have levels 4 times higher than those 
in *1*1 homozygotes. Six studies 13 40 84-87 reported a 
relation between ALDH2 polymorphisms and risk for 
hnC, and all were conducted in Japanese populations. 
Four studies 35 79 80 82 showed a significantly increased 
risk for hnC in *1/*2 heterozygotes compared with 
*1/*1 homozygotes 2. mc Kay et al. found that five ge-
netic variants at three loci, 4q21, 4q23 and 12q24, were 
significantly associated with hnC risk 10.
•  ADH isoenzymes, which are primarily involved in etha-
nol oxidation, consist of subunits encoded by ADH2 
and ADH3. in contrast to ADH2, ADH3 is highly poly-
morphic in Caucasians. of the 2 allelic variants, the 
ADH3*1 allele is associated with higher enzyme activ-
ity than the ADH3*2 allele and occurs in Caucasians at 
frequencies of 55-63%. in 5 19 37 88-90 of 8 studies 19 37 88-93, 
ADH3*2/*1 heterozygotes showed decreased risk for 
hnC compared with *2/*2 homozygotes. however, in 
6 19 37 88 91-93 of 9 studies 19 37 88-93, ADH3*1/*1 homozy-
gotes showed increased risk for hnC 2. in accordance 
with mc Kay and co-workers, three independent vari-
ants,  ADH1B  (rs1229984),  ADH7  (rs1573496)  and 
ADH1C (rs698), have also been associated with hnC 
risk in european populations. The effects of these three 
variants  were  generally  present  for  each  hnC  sub-
sites, but more pronounced in oesophageal cancers and 
males. Strong heterogeneity was found with rs1229984 
when stratifying by alcohol consumption.
•  Polymorphisms in X-ray repair cross complementing 
protein 1 (XRCC1), including Arg194Trp, Arg280his 
and Arg399gln,  have  been  described. Although  the 
biochemical and biologic characteristics of the variants 
have not been determined, it has been reported that 
individuals with the XRCC1 399gln variant show in-
creased sister chromatid exchange after treatment with 
a tobacco-specific carcinogen 2. however, as already 
described by gonzalez et al. 94 in 2002, the functional 
roles for these polymorphisms are unknown, even if genetic susceptibility to head-neck cancer
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they are associated with high risk in non-smokers and 
in non-alcohol drinkers. The results for the relationship 
between XRCC1 polymorphisms and hnC are incon-
sistent as highlighted in two meta-analyses published 
in 2005.
•  Xeroderma  pigmentosum  complementary  group  D 
(XPD) has 2 functions: nucleotide excision repair and 
basal transcription as part of the transcription factor 
complex, TFiih 95. Polymorphisms, such as 22,541AC 
and 35,931CA, have been identified. individuals ho-
mozygous for the variant genotype of XPD have sub-
optimal dnA repair capacity 96. hiyama et al. in 2008 
analyzed 4 studies 97-100 of the genotype at nucleotide 
22,541 and 5 studies 98-102 of the genotype at nucleotide 
35,931 of XPD. According to these investigations, in-
dividuals homozygous for the variant genotype of XPD 
have suboptimal dnA repair capacity 96.
•  The CCND1 gene encodes a key cell cycle regulatory 
protein, cyclin d1, which regulates transition from g1 
to the S phase during cell division. high activity of cyc-
lin d1 leads to premature cell passage through the g1-S 
transition, resulting in propagation of unrepaired dnA 
damage and accumulation of genetic errors, therefore 
leading to selective advantage for abnormal cell prolif-
eration 103. numerous studies found that Cd1 g/A870 
single nucleotide polymorphism is associated with two 
different  splice  variant  transcripts:  Cd1a  and  Cd1b. 
Cd1a encodes for the full-length native form of the Cd1 
protein, and Cd1b encodes for a truncated alternate Cd1 
protein 104. This strongly suggests that individuals with 
numerous copies of the CCND1-870A are more likely to 
bypass the g1-S checkpoint, thus contributing to cancer 
development 103. hiyama et al. evaluated six ors 105-110 
from 9 studies 105-113 of the gA genotype vs. the gg gen-
otype which at nucleotide position 870 were < 1, and 7 
ors 105-110 for the AA genotype vs gg which were < 1 2. 
These results are statistically relevant and suggest that 
the A allele may be associated with decreased risk for 
hnC. on the basis of the studies published in 2011, cell 
cycle regulation may play a role in oral carcinogenesis 
and the CCND1 rs9344 polymorphism may be a useful 
biomarker for oral oncology 114. The data reported in the 
literature indicates that Cd1 genotype and protein ex-
pression as important risk markers for laryngeal cancer 
and suggest future trials targeting upstream regulators of 
Cd1 transcription 104.
•  Dysfunction in the P53 tumour suppressor gene (locat-
ed at 17p13) is implicated in many cancers, including 
hnC, and has received the most attention. The produc-
tion of p53 is increased in response to cellular insults 
or dnA damage, and p53 then induces cell cycle arrest 
at the g1/S junction. if the damage is irreparable, p53 
can initiate cell death by apoptosis. The steady-state 
concentration of p53 in normal cells is low, and the 
half-life of normal (wild type) p53 is short. in contrast, 
if the p53 gene is mutated, the genetic product is often 
present at high concentrations. even if the concentra-
tion is important, mutations in the TP53 gene frequently 
occur. mutations in p53 are present in 50-60% of head 
and neck cancers 115-116. hiyama published in 2008 that 
a g-to-C polymorphism in codon 72 of exon 4 results 
in an Arg-to-Pro substitution. Although both variants 
are morphologically wild-type, the Pro/Pro genotype is 
less effective in suppressing cellular transformation 117. 
individuals with the Pro/Pro genotype showed a higher 
risk for hnC than individuals with the Arg/Arg geno-
type in 15 118-132 of 19 studies 64 118-135. in 2010, Zhou 
provided a more precise estimation of the relationship 
between P53 and head and neck cancers. There was no 
evidence to suggest that TP53 codon 72 polymorphisms 
may be a risk factor for oral carcinoma 136. however, 
TP53 codon 72 polymorphisms may be a risk factor for 
nPC. The homozygote Pro/Pro genotype could signifi-
cantly increase susceptibility to nPC, whereas the Arg 
allele markedly decreases nPC risk 137. Bradford 138 and 
Poeta 139 published that mutations in tumour protein 
53 (TP53) may be correlated with aggressive hnSCC 
disease and relative radioresistance. in the december 
2007 issue of the New England Journal of Medicine, 
a team of nidCr grantees and colleagues evaluated 
the prognostic value of TP53 mutations in 420 head-
and-neck cancer patients treated with surgery only and 
whose survival was tracked for several years thereafter. 
detecting TP53 alterations in the tumours of 53% of 
participants, it was found that these mutations were as-
sociated with decreased overall survival.
•  P73 encodes a member of the p53 family of transcrip-
tion  factors  involved  in  cellular  responses  to  stress 
and development. it maps to a region on chromosome 
1p36 that is frequently deleted in neuroblastoma and 
other tumours, and thought to contain multiple tumour 
suppressor genes. The demonstration that this gene is 
monoallelically expressed (likely from the maternal al-
lele) supports the notion that it is a candidate gene for 
neuroblastoma. many transcript variants resulting from 
alternative splicing and/or use of alternate promoters 
have been found for this gene, but the biological va-
lidity and the full-length nature of some variants have 
not been determined (refSeq, Feb 2011). hypermeth-
ylation of TP73 is reported in nasopharyngeal carci-
nomas with a frequency of 20% 140. Ferru in 2006 141, 
by comparison to normal thyroid tissue surrounding 
tumours, observed significant down regulation of TP73 
transcripts in adenomas and in differentiated carcino-
mas. Chen published in 2004 142 that p73 expression 
may be associated with the differentiation of oral strati-
fied squamous epithelium, an early event in human oral 
carcinogenesis, and associated with the nodal status of 
patients with oral carcinoma and a possible indicator 
for malignant change of oral epithelial dysplasia.g. Cadoni et al.
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Discussion and conclusions
molecular epidemiologic studies have provided evidence 
that individual susceptibility to cancer is mediated by both 
genetic and environmental factors 4 6-14 33 34 43 50 128 135 140 143. 
interest in the role of genetic polymorphisms in hnC 
has increased recently, possibly due to advances in dnA 
analysis technologies or our knowledge of the human ge-
nome.
The most intensively-studied genes are those encoding en-
zymes that metabolize carcinogens and include GSTM1, 
GSTT1 and GSTP1. This is likely because these variants 
are well characterized, and increased cancer risk associ-
ated  with  these  variations  is  plausible. A  considerable 
amount of work has been done on these genes in relation 
to risk for hnC. one of the major problems of these stud-
ies is that many have a small sample size (< 100 cases 
or < 100 controls) 2. overall, by summarizing the results 
of the published meta-analyses of the association between 
genetic polymorphisms and hnC risk, a statistically risk 
was reported for 3 polymorphisms, namely:
•  Glutathione S-transferase (GSTM1), 2 meta-analyses;
•  Glutathione S-transferase (GSTT1), 1 meta-analysis;
•  Human  microsomal  epoxide  hydrolase  (EPHX1),  2 
meta-analyses.
As demonstrated by 2 meta-analyses, GSTM1 deficiency 
was  associated  with  laryngeal  cancer  risk.  Strikingly, 
the results showed lack of associations between GSTM1 
null genotypes and laryngeal cancer risk in Caucasians 
or Asians. The combination of the GSTM1 null plus the 
CYP1A1 (m1m2) variant genotypes increased the risk of 
oral and pharyngeal cancer 26. Previous meta-analysis and 
pooled analysis have reported an association between the 
GSTM1 null genotype and head and neck tumours, but did 
not analyze ethnic specific or subsite specific differences. 
varela-lema et al. 33 evaluated ethnic specific and subsite 
specific differences in a pooled analysis, and confirmed 
that there was no association of the GSTM1 null geno-
type with oral and pharyngeal cancers in Caucasians. Al-
though not statistically significant, African American and 
African populations seemed to be almost twice as likely 
to have the GSTM1 null genotype. This lack of statistical 
significance might also be attributed to the small number 
of African American and African subjects included in this 
pooled analysis. There was also an association between 
GSTM1 null genotypes and smoking status 34.
deletion of GSTM1 might contribute to the tumorigen-
esis and progression of nasopharyngeal cancer 26. GSTT1 
deletion might also have an association with increased 
nasopharyngeal cancer risk, as demonstrated by a meta-
analysis. A successive study has demonstrated that the 
data failed to show a significant association of GSTT1 
null genotype with increased susceptibility to nasopha-
ryngeal cancer. This discrepancy might be due to several 
reasons. For GSTT1, a gene that is highly conserved dur-
ing evolution, major ethnic differences exist in frequency 
distribution. in east Asia, highest percentages of individ-
uals with the GSTT1 null genotype have been reported. 
interestingly, the incidence of nasopharyngeal cancer is 
high in east Asia, but is low in other regions worldwide. it 
thus appears that GSTT1 deletion may have an association 
with increased nasopharyngeal cancer risk. nevertheless, 
it indicates that although many people in east Asia carry 
GSTT1 null genotype, but only a relatively small number 
of people develop nasopharyngeal cancer, implying that 
GSTT1 deletion might not be a key event increasing sus-
ceptibility to nasopharyngeal cancer 34. Additionally, as 
only 4 small studies have been published on GSTT1, it is 
likely that the discrepancy may be due to chance because 
studies with small sample size may have insufficient sta-
tistical power to detect a slight effect or may yield a fluc-
tuated risk estimate 26. Zhang et al. did not find a signifi-
cant association between the null genotype of GSTT1 and 
oral cancer risk in Asians or Caucasians 34. heterogeneity 
exists between studies, and a significant multiplicative in-
teraction between the null genotype of GSTT1 and smok-
ing status has not been found, although small sample sizes 
may be a reason for the lack of statistical significance.
Two  meta-analyses  for  the  EPHX1  gene  demonstrated 
dissimilar results. The y113h allele may have a potential 
protective effect on tobacco-related carcinogenesis of lung 
and hnC, whereas the homozygous variant of h139r 
allele, instead, may have a harmful effect 83. moreover, 
cigarette-smoking status may influence the association of 
EPHX1 enzyme activity and the related cancer risk 83.
many primary studies had focalized their attention on al-
cohol metabolic genes. in particular, mc Kay et al. found 
that five genetic variants at three loci, 4q21, 4q23 and 
12q24, were significantly associated with hnC risk. The 
12q24 variant is positioned in an extended region of ld 
that contains multiple genes. Candidate genes include the 
aldehyde dehydrogenase 2 (ALDH2) 10.
in accordance with mc Kay and co-workers, three inde-
pendent variants of the ADH gene have been associated 
with hnC risk in european populations. The effects of 
these three variants were generally present for each hnC 
subsites, but more pronounced in esophageal cancers and 
males. Strong heterogeneity was found with rs1229984 
when  stratifying  by  alcohol  consumption.  notably,  an 
association was observed in “ever drinkers-never smok-
ers”, but not in “never drinkers-ever smokers”, suggest-
ing that the effect with the rs1229984 variant is mediated 
through alcohol rather than tobacco smoking. in contrast, 
the lack of heterogeneity for rs1573496 when stratifying 
by alcohol use may imply differences in the mechanism 
of carcinogenesis among these ADH variants 10. Several 
studies have suggested rs1229984 may influence alcohol 
consumption behaviour 10 144-147.
The integration of genome-based knowledge into health-
care has the potential to improve primary and secondary genetic susceptibility to head-neck cancer
7
prevention 148. Among the greatest promises of genomic 
medicine is that the unravelling of the genetic origins of 
common diseases will eventually lead to individualized 
medicine, in which prevention and treatment strategies 
are personalized on the basis of the results of predictive 
genetic  tests.  Findings  from  meta-analyses  of  genetic 
association studies have the potential to provide a com-
prehensive view of the impact of genetic risk factors in 
disease aetiology, especially when exploring gene-envi-
ronment interactions 11.
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